Emerging alternatives against Clostridioides difficile infection
Abstract
No abstract availableKeywords
This publication has 101 references indexed in Scilit:
- ComparativeIn VitroActivities of SMT19969, a New Antimicrobial Agent, against Clostridium difficile and 350 Gram-Positive and Gram-Negative Aerobic and Anaerobic Intestinal Flora IsolatesAntimicrobial Agents and Chemotherapy, 2013
- Intestinal Dysbiosis and Depletion of Butyrogenic Bacteria in Clostridium difficile Infection and Nosocomial DiarrheaJournal of Clinical Microbiology, 2013
- Commensal Clostridia: leading players in the maintenance of gut homeostasisGut Pathogens, 2013
- Novel High-Molecular-Weight, R-Type Bacteriocins of Clostridium difficileJournal of Bacteriology, 2012
- Fidaxomicin: A Novel Macrocyclic Antibiotic Approved for Treatment of Clostridium difficile InfectionClinical Infectious Diseases, 2011
- “Nanoantibiotics”: A new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant eraJournal of Controlled Release, 2011
- Fidaxomicin versus Vancomycin forClostridium difficileInfectionNew England Journal of Medicine, 2011
- Inhibiting the Initiation ofClostridium difficileSpore Germination using Analogs of Chenodeoxycholic Acid, a Bile AcidJournal of Bacteriology, 2010
- Nitazoxanide versus Vancomycin inClostridium difficileInfection: A Randomized, Double‐Blind StudyClinical Infectious Diseases, 2009
- A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoeaJournal of Antimicrobial Chemotherapy, 2004